SYSTEMS GENETICS TO DETERMINE RISK OF DEVELOPING DIABETES COMPLICATIONS
Emeritus Professor Grant Morahan, Professor of Diabetes Research, University of Western Australia Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research), Perth, Australia & Honorary Professor, Baker Department of Cardiometabolic Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | December 2025
Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.
As a member of the Steering Committee of the Type 1 Diabetes Genetics Consortium, he worked to design the global study recruiting and characterising T1D genetics, which resulted in identification of over 40 T1D risk genes. The culmination of this program, for which Prof Morahan was PI of the Asia-Pacific Network, was published in Nature Genetics (41:703-707) and has been cited 1579 times.
Currently, he is a member of the Steering Committee of the Environmental Determinants of Islet Autoimmunity (ENDIA) Study, the only study in the world investigating T1D families to follow at-risk babies from pregnancy through childhood. Completing recruitment in 2020, the study already has 40 publications.
His latest discovery involves next-generation algorithms that are able to predict whether a person will be genetically high/low risk of developing a number of complex genetic diseases. Professor Morahan is working toward commercialising these genetic tests so they can benefit the public and the healthcare system.
During his career, Prof Morahan has supervised 23 postgraduate students and mentored nine postdoctoral positions. Since 2003, Prof Morahan has applied for and received close to $20 million in research funds, both nationally and internationally. He has 299 academic publications, 17,0744 citations and has an h-index of 60.
Source: Supplied
You Might also like
-
Paramedicine workforce across Australian & New Zealand
Liz Thyer is an Associate Professor in the Western Sydney University Paramedicine program and is passionate about innovations and excellence in health sciences teaching and learning.
She was an advanced life support paramedic with Ambulance Victoria for 11 years including roles as a clinical instructor and peer support officer. She has previously worked at Victoria University with the Paramedic programs and at Deakin University in Learning Futures.
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Radiation therapy techniques and combination treatments for sarcoma
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
https://orcid.org/0000-0002-8562-7325